SCHEMBL23925997

SCHEMBL23925997

COc1cc(Oc2cccc(-c3ccc4cn[nH]c4c3)n2)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 6/20 0.43
FGFR1 P11362 6/20 0.43
FGFR3 P22607 1/20 0.42
TGFBR1 P36897 2/20 0.41
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
SYK P43405 3/20 0.39
HSD17B14 Q9BPX1 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CB P42338 1/20 0.38
DDR2 Q16832 1/20 0.38
PDE4B Q07343 1/20 0.38
RIPK2 O43353 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510871 0.85 HSD17B14 (0.56) FGFR2FGFR1FGFR3TGFBR1FFAR4
SCHEMBL23943318 0.85 HSD17B14 (0.56) FGFR2FGFR1FGFR3TGFBR1FFAR4
SCHEMBL25183927 0.80 FFAR4 (0.40) KDM4ENPC1LMNARAB9ASMN1; SMN2
SCHEMBL30510804 0.80 FGFR1 (0.49) FGFR2FGFR1RAF1BRAFKDM4E
SCHEMBL23925971 0.80 FGFR1 (0.49) FGFR2FGFR1RAF1BRAFKDM4E
SCHEMBL23943402 0.79 HSD17B14 (0.39) RAF1BRAFFFAR4SYKHSD17B14
SCHEMBL30510826 0.73 FFAR4 (0.36) FGFR1FFAR4SYKHSD17B14PDE4B
SCHEMBL23943576 0.73 FFAR4 (0.36) FGFR1FFAR4SYKHSD17B14PDE4B
SCHEMBL23943229 0.73 HSD17B14 (0.59) NPC1RAB9ASMN1; SMN2FFAR4HSD17B14
SCHEMBL23926177 0.71 HSD17B14 (0.66) FGFR2FGFR1FGFR3LMNAHSD17B14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 FGFR2 3035/4885FGFR1 1591/4885FGFR3 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.